Background: Aurora kinase B (AURKB) is an important carcinogenic factor in various tumors, while its role in clear cell renal cell carcinoma (ccRCC) still remains unclear. This study aimed to investigate its prognostic value and mechanism of action in ccRCC.
82 database (https://portal.gdc.cancer.gov/). In addition, Drug sensitivity data of ccRCC cell lines 83 were obtained from genomics of drug sensitivity in cancer (GDSC) database 84 (https://portals.broadinstitute.org/ccle/about). We then utilized R software (https://www.r-85 project.org/) to process all data. 86 Firstly, we extracted clinical data of ccRCC patients and data of gene expression profiles. We 87 then obtained clinical data of 530 patients who possessed complete OS information and a gene 88 expression matrix document. Secondly, we obtained expression of AURKB data from the gene 89 expression matrix document and analyzed the relationship between expression of AURKB and 90 clinical parameters including age, gender, histological grade, pathological stage, T stage, N stage, 91 and M stage. Thirdly, the ccRCC patients be divided into two groups based on median value of 92 AURKB expression (high AURKB expression group and low AURKB expression group) and 93 analyzed their overall survival (OS) and disease-free survival (DFS). Fourthly, we utilized some 94 clinical parameters, that correlated with prognosis of ccRCC, and AURKB to construct a 95 prognostic model. Finally, we analyzed that the difference between sensitivity of AURKB 96 targeted drug and other targeted drugs for ccRCC. 97 98 Gene set enrichment analysis 99 Gene expression profiles of ccRCC patients were divided into two groups (high expression group 100 and low expression group) according to the median value of expression of AURKB. GSEA was 101 utilized to detect potential mechanisms underlying the effect of AURKB expression on ccRCC 102 prognosis. Gene set permutations were performed 1000 times for each analysis. Gene sets with a 103 p-value < 0.05 and false discovery rate (FDR) < 0.05 were regarded as significantly enriched. 104 105 Statistical analysis 106 All statistical analyses were performed through R software and p < 0.05 was regarded as 107 statistically significant. The relationship between expression levels of AURKB and clinical 108 parameters was analyzed via the Wilcoxon signed-rank test, Kruskal-Wallis test and logistic 109 regression. The correlation between expression levels of AURKB, and patients'OS and DFS 110 were analyzed using the Kaplan-Meier method. Univariate Cox analysis was used to select 111 possible prognostic factors, and multivariate Cox analysis was utilized to verify the correlations 112 between AURKB mRNA expression and survival along with other clinical features. A receiver 113 operating characteristic (ROC) curve was used to evaluate the accuracy of models that predicted 114 prognosis using the survival ROC package. An area under the curve (AUC) value of 0.75 or 115 bigger was deemed an excellent predictive value, and values of 0.6 or larger were regarded as 116 acceptable for survival predictions. The chi-square test be used to compare difference between 117 sensitivity of target drugs in ccRCC cell lines. 118 119 Results 120 Clinical parameters of patients 121 The clinical data of 530 ccRCC patients were obtained from the TCGA database, and included 122 age, gender, histological grade, pathological stage, survival, and outcome, etc. (Table 1) . 123 124 High AURKB expression in ccRCC 125 Expression levels of AURKB in 539 ccRCC and 72 normal kidney tissues were compared via 126 Wilcoxon signed-rank test, and the results showed that AURKB was highly expressed in ccRCC 127 compared to normal kidney tissues (p < 0.05) ( Fig. 1A) . We further analyzed the expression of 128 AURKB in 72 pairs of ccRCC tissues and matched non-cancerous adjacent tissues using 129 Wilcoxon singed-rank test, and found that AURKB was significantly overexpressed in ccRCC 130 tissues (p < 0.05) ( Fig. 1B) . These results suggested that AURKB may be a carcinogenic gene in 131 ccRCC. 134 The relationship between AURKB expression and patients' clinical parameters was analyzed by 135 R software. Results indicated that with the increase of AURKB expression, these clinical 136 parameters (histological grade, pathological stage, T stage, N stage and M stage) also elevated 137 (all p < 0.05). Furthermore, expression of AURKB in male was higher than female (p < 0.05) 138 (Fig. 2) . 139 Logistic regression analysis shown that increased AURKB expression in ccRCC was obviously 140 correlated with gender (OR = 1.49 for Female vs. Male, p = 0.029), histological grade (OR = 141 2.44 for G1/G2 vs. G3/G4, p = 6.97E-07), pathological stage ( OR = 1.17 for stage I vs. stage III, 142 p = 0.000; OR = 3.62 for stage I vs. stage IV, p = 2.42683E-06 ), TNM stage (OR = 2.84 for 143 T1/T2 vs. T3/T4, p = 3.12E-08; OR = 4.75 for N0 vs. N1, p = 0.017; OR = 2.99, for M0 vs. M1, 144 p = 4.8776E-05) ( Table 2 ). These results indicated that ccRCC with increased AURKB 145 expression is prone to progress to a more advanced stage, lymph node metastasis distant 146 metastasis. 149 To further understand the prognostic role of AURKB expression in ccRCC, all ccRCC patients 150 were categorized according to the median AURKB expression value (high AURKB expression 151 group and low AURKB expression group). Patients who lacked complete clinical data were 152 excluded from the analysis. Kaplan-Meier survival analysis indicated that the high AURKB 153 expression group had worse prognosis compared with the low AURKB expression group (p < 154 0.05) (Fig. 3) . The univariate analysis indicated that high AURKB expression was associated with 155 poorer OS and DFS (p < 0.05). Other clinical parameters, such as pathological stage and 156 histological grade, also correlated with worse OS and DFS (p < 0.05) (Table 3) . 157 To confirm the prognostic value of AURKB expression, multivariate analysis was performed. 158 The results showed that age, histological grade, pathological stage and AURKB expression were 159 independently associated with OS (p < 0.05), and histological grade, pathological stage and 160 AURKB were independently correlated with DFS (p < 0.05). Overall, these results suggest that 161 AURKB is an independent prognostic factor of ccRCC ( Fig. 4 and Table 3 ). 204 proliferation of NSCLC cells via inhibiting the p53-related pathway. In addition, expression of 205 AURKB has also been associated with drug resistance in NSCLC. Overexpression of AURKB 206 increased drug resistance in NSCLC cells, whereas AURKB knockdown re-sensitized NSCLC 207 cells to chemotherapeutic drugs (Yu et al., 2018). In colorectal cancer (CRC), AURKB has also 208 been shown to act as an important oncogenic factor, be involved in the development of CRC, and 209 promoted drug resistance and progression of CRC though regulation of the Wnt signaling . All these studies have suggested that AURKB promotes 212 carcinogenesis and is associated with drug resistance.
133 Correlations between AURKB expression and clinical parameters in ccRCC patients

148 Prognostic role of AURKB expression in ccRCC Patients
213
In this work, we sought to identify the role of AURKB expression in ccRCC progression, 214 particularly, its role as a prognostic factor in ccRCC. Moreover, we also attempted to screen 215 AURKB-related signaling pathways in ccRCC to contribute to the understanding the potential 216 mechanism involved in the regulation of ccRCC development by AURKB. 217 Firstly, we compared that expression of AURKB in ccRCC and normal tissues. The results 218 showed that AURKB was overexpressed in ccRCC tissues compared to normal tissues, and its 219 expression was associated with pathological stage, histological grade, T stage, M stage, and N 220 stage.
221
Secondly, Kaplan-Meier survival analysis showed that compared to the low AURKB 222 expression group, the high AURKB expression group of patients had poorer OS and DFS. 223 Moreover, some variables were also associated with the prognosis of ccRCC patients, including 224 pathological stage, histological grade, T stage, and M stage. In addition, multivariate analysis 225 confirmed that AURKB expression was a prognostic factor. Another, the drug sensitivity analysis 226 of ccRCC cell lines suggested that various cell lines were sensitive to Genentech Cpd 10, and 227 AURKB might be a promising target to treat ccRCC. 228 Finally, we constructed prognostic models of AURKB expression, and the area under the 229 curve (AUC) values proved that the new prognostic models can accurately predict OS and PFS. 230 Furthermore, AURKB related signaling pathways in ccRCC were analyzed by GSEA, and results 231 suggested that intestinal immune network for IgA production, cytokine-cytokine receptor 232 interaction, natural killer cell mediated cytotoxicity, cell cycle and cell adhesion molecules Additionally, in the present study, 255 we found that AURKB is a promising biomarker in the treatment of ccRCC and a predictor of 256 prognosis.
257
Inevitably, our study also has several limitations. Firstly, the data we analyzed in the present 258 study were extracted from several public databases, which had not been verified. Secondly, the 259 mechanisms by which AURKB regulates the occurrence and progression of ccRCC need further 260 exploration. Finally, our study found that ccRCC cell lines were more sensitive to AURKB-261 targeting drug (Genentech Cpd 10) than the conventional targeted drugs (Cabozantinib and 262 Axitinib). However, more studies are necessary to identify whether AURKB could be used as a 263 target for ccRCC treatment. In summary, our study suggests that AURKB is over-expressed in ccRCC, and it is a 267 valuable prognostic factor for predicting OS and DFS of ccRCC patients. AURKB can promote 268 development of ccRCC via various signaling pathways including intestinal immune network for 269 IgA production, cytokine-cytokine receptor interaction, natural killer cell mediated cytotoxicity, 270 cell cycle and cell adhesion molecules (CAMs). In addition, AURKB might be a promising 271 therapeutic target for ccRCC. However, more research is required to verify the findings of this 272 study.
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